Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.
about
Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles13C- and 15N-Labeling Strategies Combined with Mass Spectrometry Comprehensively Quantify Phospholipid Dynamics in C. elegansInherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involvedThermodynamics and 2H NMR study on the insertion of small quinones into a discotic nematic lyotropic liquid crystal.Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape.Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness.Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticlesDevelopment of a CERT START Domain-Ceramide HTRF Binding Assay and Application to Pharmacological Studies and Screening.Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functionsSustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane LipidsHighly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.Ginkgolide B protects human umbilical vein endothelial cells against xenobiotic injuries via PXR activation.Cholesterol dependent uptake and interaction of doxorubicin in mcf-7 breast cancer cellsSelective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapyImportance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2.Applications of nanoparticles in the detection and treatment of kidney diseasesDownregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil.Membrane-drug interactions studied using model membrane systemsNucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosis.Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells.Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence.Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma.Nanoparticle-based drug delivery in cancer: the role of cell membrane structures.Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - An illustration with firsthand examples.Pivotal role of human stearoyl-CoA desaturases (SCD1 and 5) in breast cancer progression: oleic acid-based effect of SCD1 on cell migration and a novel pro-cell survival role for SCD5.
P2860
Q27026080-A3182DC4-7FFB-4528-88C1-49F918493CC4Q27347981-0957A9EE-862B-48C4-85EA-1D29AAC0116AQ28486233-8E948088-005A-4ED5-B6C1-5DC1EA8672C8Q30797032-8747DDB6-EA8F-45C3-8821-DC8CB517F681Q33837207-A43BD26B-C61C-4B28-8711-184C12F5E5BDQ34515871-A3D5D4FE-0260-478F-B6EA-40C8B9CBEACFQ35105148-DDCD308D-2D13-4C02-AFD0-6F9F2FED35B6Q35567959-DC6D26C0-BD56-4E0A-9B21-9299AE5E9938Q36207846-65E59546-B573-470D-8B7E-1AC9BECE4ADDQ36498973-5B2045D7-1120-4794-8DBE-EB3CE3802F55Q36517999-E8056FED-BE05-4AFC-82F5-7015DF92F00BQ36579273-AAFAC24B-BEF6-46DF-AF94-4F0B7575F83FQ36820598-0FAC8325-BC3B-43EE-885D-48F3E88A382AQ36893395-85E20D18-9DE8-4D41-80EF-4DC6680771D0Q37054441-CDA43C30-DD6A-4903-B7D8-8990044F24FBQ37298541-5A9BFA6A-7541-464B-8D4F-4865951264ADQ37593963-7DB8C58B-6985-4281-A26A-6DB8579F1681Q38639666-50B5D605-39CE-4532-AD6F-643C0630F2ECQ38957716-B2BBEE51-64EF-45BE-A511-431AF146D4F3Q39270266-B72E8E72-E9D8-4280-BCE0-D528F1AA3050Q39421907-DBA7F5C7-D983-4584-954D-752A5386E5C2Q39493601-851B3B74-62AA-46A8-8CFC-3D0C527C71ACQ39537520-D8FCC3A0-B930-4CF6-8D52-0B0E88D94047Q47240392-000F4434-1F53-46E0-8209-15BC16162B88Q51118403-B6FD1734-9FA8-4F4F-B164-FFD0CC48E62DQ52561274-A38282D2-245F-4F0D-9B3F-778BB7F827DFQ55363630-167FA084-8C88-452C-AFE2-1892BDF0471E
P2860
Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug resistance in breast canc ...... ractions with membrane lipids.
@ast
Drug resistance in breast canc ...... ractions with membrane lipids.
@en
Drug resistance in breast canc ...... ractions with membrane lipids.
@nl
type
label
Drug resistance in breast canc ...... ractions with membrane lipids.
@ast
Drug resistance in breast canc ...... ractions with membrane lipids.
@en
Drug resistance in breast canc ...... ractions with membrane lipids.
@nl
prefLabel
Drug resistance in breast canc ...... ractions with membrane lipids.
@ast
Drug resistance in breast canc ...... ractions with membrane lipids.
@en
Drug resistance in breast canc ...... ractions with membrane lipids.
@nl
P2093
P2860
P356
P1476
Drug resistance in breast canc ...... eractions with membrane lipids
@en
P2093
Andrew Stine
Edgar Kooijman
Radhika Bhave
Sivakumar Vijayaraghavalu
Vinod Labhasetwar
P2860
P304
P356
10.1021/MP100308N
P407
P577
2010-11-11T00:00:00Z